Mohamed H. Zaki

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 799 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Paul G. Richardson, David S. Siegel, Ravi Vij et al. · Blood · 2014 · 384 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Meletios Α. Dimopoulos, Antonio Palumbo, Paolo Corradini et al. · Blood · 2016 · 162 citations · Full text

Medicine, Hematology, Oncology +15

Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice

Lauren P. Wallner, Jinlu Dai, June Escara‐Wilke et al. · Cancer Research · 2006 · 146 citations · Full text

Medicine, Endocrinology, Oncology +16